Vincerx Pharma Inc（VINC）股票分析

$0.100

-0.025 (-24.98%)收盤時

Loading chart…

High: 0.131
Open: 0.126
VWAP: 0.10
Vol: 4.48M
Mkt Cap: 21.86M
Low: 0.081
Amount: 465.44K
EV/EBITDA, TTM: 0.00

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers.

估值指標

The current forward P/E ratio for Vincerx Pharma Inc (VINC) is -0.04, compared to its 5-year average forward P/E of -0.94.

Forward P/E

Fair

5Y Average P/E

-0.94

Current P/E

-0.04

高估

0.32

低估

-2.20

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

高估

0.00

低估

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

高估

0.00

低估

0.00

事件時間軸

2025-04-17 (ET)

16:47:06

Vincerx Pharma announces plan to delist from Nasdaq

2025-04-08 (ET)

16:19:04

Vincerx terminates letter of intent with Global Digital, initiates wind down

2025-03-18 (ET)

08:55:56

Vincerx Pharma announces non-binding LOI for Qumulus AI combination

2025-02-28 (ET)

16:06:55

Vincerx Pharma announces termination of reverse merger term sheet

2025-01-23 (ET)

15:22:56

Vincerx Pharma board aproves 1-for-20 reverse stock split

Show More Events

資訊

VINC FAQ — answered by Alphio AI

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。